[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-445763-105":59,"doc-detail-445763-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","pp40-enoxaparin-synthesis-of-evidence-for-expanding-the-current-national-clinical-protocol-and-therapeutic-guidelines","PP40 Enoxaparin: Synthesis of Evidence for Expanding the Current National Clinical Protocol and Therapeutic Guidelines","","Evaluating enoxaparin for thromboprophylaxis in pregnant or postpartum women at risk of venous thromboembolism, this study aimed to support the expansion of Brazil’s national Clinical Protocols and Therapeutic Guidelines. Searches in MEDLINE, LILACS, and Embase (January 2024) with a systematic-review filter identified eight eligible studies, using Rayyan for screening. For budget impact, hospitalization costs were calculated from enoxaparin values and doses, local hospital consumption, and Bahia epidemiological data.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pp40-enoxaparin-synthesis-of-evidence-for-expanding-the-current-national-clinical-protocol-and-therapeutic-guidelines/445763/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pp40-enoxaparin-synthesis-of-evidence-for-expanding-the-current-national-clinical-protocol-and-therapeutic-guidelines/445763.png","ImageObject",300,407,{"name":92,"@type":93},"River Wang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-05","2026-09-29",true,{"@type":102,"interactionType":103,"userInteractionCount":14},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main purpose of evaluating enoxaparin in this study?","Question",{"text":112,"@type":113},"To assess efficacy, safety, and costs of enoxaparin for thromboprophylaxis in pregnant or postpartum women at risk for VTE, supporting expansion of Brazil’s national clinical protocols and therapeutic guidelines.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were studies selected for the evidence synthesis?",{"text":117,"@type":113},"The authors searched MEDLINE, LILACS, and Embase (January 2024) using a strategy combining the target population, enoxaparin/low molecular weight heparin, and systematic-review filters, then excluded duplicates and applied eligibility criteria in Rayyan.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key findings on outcomes and safety?",{"text":121,"@type":113},"Results indicated reduced thromboembolic events and VTE in high-risk perinatal pregnant and certain postpartum women without antepartum anticoagulation, alongside increased hemorrhagic events and a significant rise in allergic reactions, including effects worsening during in vitro fertilization.",{"name":123,"@type":110,"acceptedAnswer":124},"How was the budget impact estimated?",{"text":125,"@type":113},"Avoidable hospitalization costs and budget impact were calculated using enoxaparin values and doses, local hospital consumption, and epidemiological data, including hospitalization cost calculations for pregnant women (n=259) with VTE in Bahia.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},445763,1791174037,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":14,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":8,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":81},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","PP39 Monitoring Clinical Trial Registers In The Context Of A Systematic Review On Vitamin D For COVID-19  \nTrinidad Sabalete-Moya (trinidad. [sabalete@juntadeandalucia.es](sabalete@juntadeandalucia.es)),  \nRebeca Isabel-Gómez and Juan Antonio Blasco Amaro  \nIntroduction: Clinical trial registries provide relevant information to address publication bias in systematic reviews. However, monitoring these registries is a complex process. Results are rarely posted in registries, and finding publications in journals requires a laborious search across multiple resources. We aimed to monitor registries of randomized clinical trials, results posted on platforms, and articles published in journals in the context of a rapid review to inform decision-makers.  \nMethods: We searched [ClinicalTrials.gov](ClinicalTrials.gov) and the World Health Organization International Clinical Trials Registry Platform from April2020to November 2024as part ofa systematic search on the use of vitamin D in COVID-19, including the MEDLINE, Embase, Web of Science, and the Cochrane Library databases. We collected data such as the study start date, sample size, principal trial characteristics, population, intervention, control, and main outcome. We reviewed new register monitoring results published in databases or platforms and assessed each report’s update frequency until November 2024 . Results: We found 54 unique register numbers with this different status information: 29 trials were completed, two terminated, four active(one recruiting and three not yet recruiting), two were ongoing, one had recruitment and regulatory approvals pending, 11 had unknown status, one was prematurely ended, and two were withdrawn. Two clinical trials were matched with one study published. In total, 26 trials had results published in journals. However, only two trials posted results on the platform. In the last review, 25 trials remained without results, and related publications were not found. Conclusions: Searching clinical trial registries as part ofa systematic review strategy is a necessary source for addressing publication bias. Monitoring clinical trial registries provides relevant information on the development and length of trials, identifying gaps and failures to assist research. Lack ofupdated information on registries, and finding accurate and worthy information about trials, can result in a time consuming and sometimes unsuccessful process.  \nPP40 Enoxaparin: Synthesis of Evidence for Expanding the Current National Clinical Protocol and Therapeutic Guidelines  \nGleidson Cardoso Spinola,  \nBárbara de Castro dos Santos Silva,  \nCarolina Santos Silva ([carolina.silva@saude.ba.gov.br](carolina.silva@saude.ba.gov.br)), Manuela Fernandes de Almeida Mello and  \nRouseli Gonçalves de Menezes  \nIntroduction: Venous thromboembolism (VTE) prevention for women with additional risk factors during pregnancy is centered on anticoagulant therapy, with enoxaparin as the anticoagulant offchoice. This study evaluated the efficacy, safety, and costs of enoxaparin for thromboprophylaxis in pregnant or postpartum women at risk for VTE, aiming to expand access to the Brazilian national Clinical Protocols and Therapeutic Guidelines (PCDT) . Methods: A search was performed in the MEDLINE, LILACS, and Embase databases (January 2024) using a strategy that combined target population, enoxaparin, and low molecular weight heparin; filters for systematic review (SR) with or without meta-analysis; and publications up to five years, without language restriction. Duplicate exclusion and study eligibility were performed using Rayyan. Only eight studies met the pre-established criteria. For budget impact, enoxaparin values and doses, local hospital consumption, and epidemiological data were used. The daily, average, and annual costs of hospitalization of pregnant women (n=259) with VTE in the State of Bahia were calculated.  \nResults: Results showed a reduction of thromboembolic events; a reduction of VTE","cbCaiueGjEg2zycp","https://ap.wps.com/l/cbCaiueGjEg2zycp","pdf",33324,"English","# Introduction\n# Methods\n# Results\n# Conclusions","[{\"question\":\"What was the main purpose of evaluating enoxaparin in this study?\",\"answer\":\"To assess efficacy, safety, and costs of enoxaparin for thromboprophylaxis in pregnant or postpartum women at risk for VTE, supporting expansion of Brazil’s national clinical protocols and therapeutic guidelines.\"},{\"question\":\"How were studies selected for the evidence synthesis?\",\"answer\":\"The authors searched MEDLINE, LILACS, and Embase (January 2024) using a strategy combining the target population, enoxaparin/low molecular weight heparin, and systematic-review filters, then excluded duplicates and applied eligibility criteria in Rayyan.\"},{\"question\":\"What were the key findings on outcomes and safety?\",\"answer\":\"Results indicated reduced thromboembolic events and VTE in high-risk perinatal pregnant and certain postpartum women without antepartum anticoagulation, alongside increased hemorrhagic events and a significant rise in allergic reactions, including effects worsening during in vitro fertilization.\"},{\"question\":\"How was the budget impact estimated?\",\"answer\":\"Avoidable hospitalization costs and budget impact were calculated using enoxaparin values and doses, local hospital consumption, and epidemiological data, including hospitalization cost calculations for pregnant women (n=259) with VTE in Bahia.\"}]","PP40 Enoxaparin: Synthesis of Evidence for Expanding the Current National Clinical Protocol and Therapeutic Guidelines | PDF",1790712659]